You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TAk-935

Showing 26 - 50 of 338
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Narcolepsy Type 1 (NT 1) Trial in Worldwide (TAK-994, Placebo)

Terminated
  • Narcolepsy Type 1 (NT 1)
  • Alabaster, Alabama
  • +69 more
Oct 5, 2022

Healthy Volunteers Trial in Shanghai (TAK-279, Placebo)

Not yet recruiting
  • Healthy Volunteers
  • Shanghai, China
    Huashan Hospital Fudan University
Oct 27, 2023

Plaque Psoriasis Trial (TAK-279, Placebo, Apremilast)

Not yet recruiting
  • Plaque Psoriasis
  • (no location specified)
Oct 25, 2023

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2) Trial in Worldwide (TAK-994, Placebo)

Terminated
  • Narcolepsy Type 1 (NT1)
  • Narcolepsy Type 2 (NT2)
  • Alabaster, Alabama
  • +77 more
Oct 5, 2022

Plaque Psoriasis Trial (TAK-279, Placebo, Apremilast)

Not yet recruiting
  • Plaque Psoriasis
  • (no location specified)
Oct 12, 2023

Pancreatic Cancer, Hepatocellular Cancer, Squamous Cell Cancer (SCC) Trial in United States (TAK-500, Pembrolizumab)

Recruiting
  • Pancreatic Cancer
  • +9 more
  • Duarte, California
  • +6 more
Jan 17, 2023

Healthy Volunteers Trial in Glendale (TAK-951 Placebo, TAK-951)

Completed
  • Healthy Volunteers
  • Glendale, California
    California Clinical Trials Medical Group
Oct 11, 2022

Healthy Volunteers Trial in Tempe (TAK-227)

Not yet recruiting
  • Healthy Volunteers
  • Tempe, Arizona
    Celerion, Inc.
Apr 20, 2023

TAK-660 in Surgical Procedures for People With Hemophilia A.

Active, not recruiting
  • Hemophilia A
  • PEGylated Recombinant Factor VIII
  • Tokyo, Japan
    Takeda Selected Site
Dec 13, 2022

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) Trial in Japan (TAK-771)

Recruiting
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Multifocal Motor Neuropathy (MMN)
  • Nagoya, Aichi, Japan
  • +16 more
Feb 2, 2023

Narcolepsy Type 1 Trial in United States (TAK-861, Placebo)

Recruiting
  • Narcolepsy Type 1
  • Birmingham, Alabama
  • +6 more
Jan 31, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (TAK-981, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Birmingham, Alabama
  • +58 more
Dec 7, 2022

Thrombotic Thrombocytopenic Purpura (TTP) Trial (TAK-755)

Not yet recruiting
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • TAK-755
  • (no location specified)
Feb 9, 2023

Primary Immunodeficiency Diseases (PID) Trial (TAK-771)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • (no location specified)
Aug 22, 2022

ADHD Trial in Worldwide (Guanfacine HCl (TAK-503), Atomoxetine HCl, Placebo)

Recruiting
  • Attention Deficit Hyperactivity Disorder
  • Guanfacine hydrochloride (TAK-503)
  • +2 more
  • Dothan, Alabama
  • +42 more
Aug 19, 2022

Progressive Familial Intrahepatic Cholestasis (PFIC) Trial (TAK-625)

Not yet recruiting
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • (no location specified)
Sep 14, 2022

Alagille Syndrome (ALGS) Trial (TAK-625)

Not yet recruiting
  • Alagille Syndrome (ALGS)
  • (no location specified)
Sep 14, 2022

Parkinson Disease, Healthy Participants Trial in United States (TAK-071, Placebo)

Active, not recruiting
  • Parkinson Disease
  • Healthy Participants
  • Garden Grove, California
  • +20 more
Nov 30, 2022

NSCLC Trial in Japan (TAK-788)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Nagoya, Aichi, Japan
  • +24 more
Jul 12, 2022

Healthy Participants Trial in Las Vegas, Austin (TAK-510, TAK-510 Placebo)

Completed
  • Healthy Participants
  • Las Vegas, Nevada
  • +1 more
Oct 21, 2022

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Crohn Disease Trial in Worldwide (TAK-018, TAK-018 Placebo)

Terminated
  • Crohn Disease
  • Little Rock, Arkansas
  • +40 more
Sep 15, 2022

Unresectable Locally Advanced or Metastatic Cancer Trial in Clayton (TAK-280)

Recruiting
  • Unresectable Locally Advanced or Metastatic Cancer
  • Clayton, Australia
    Monash Medical Centre
May 5, 2022

Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • Shreveport, Louisiana
  • +3 more
Oct 3, 2023

Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • HYQVIA
  • (no location specified)
Feb 23, 2023